Artikel ; Online: Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients?
Aging clinical and experimental research
2021 Band 33, Heft 8, Seite(n) 2335–2343
Abstract: ... K antagonists (VKAs) or direct oral anticoagulants (DOACs), on prognosis of COVID-19 older patients ... in our cohort.: Conclusions: Among older patients hospitalized for COVID-19, chronic OAC therapy was not ... of a teaching hospital, referral center for COVID-19 in central Italy. We evaluated all the patients ≥ 65 years ...
| Abstract | Background: Patients hospitalized with COVID-19 experienced an increased risk of venous thromboembolism. Aims: To evaluate the effect of chronic oral anticoagulation (OAC) therapy, both with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), on prognosis of COVID-19 older patients. Methods: Single-center prospective study conducted in the Emergency Department (ED) of a teaching hospital, referral center for COVID-19 in central Italy. We evaluated all the patients ≥ 65 years, consecutively admitted to our ED for confirmed COVID-19. We compared the clinical outcome of those who were on chronic OAC at ED admission with those who did not, using a propensity score matched paired cohort of controls. The primary study endpoint was all-cause in-hospital death. Patients were matched for age, sex, clinical comorbidities, and clinical severity at presentation (based on NEWS ≥ 6). Study parameters were assessed for association to all-cause in-hospital death by a multivariate Cox regression analysis to identify independent risk factor for survival. Results: Although overall mortality was slightly higher for anticoagulated patients compared to controls (63.3% vs 43.5%, p = 0.012), the multivariate adjusted hazard ratio (HR) for death was not significant (HR = 1.56 [0.78-3.12]; p = 0.208). Both DOACs (HR 1.46 [0.73-2.92]; p = 0.283) and VKAs (HR 1.14 [0.48-2.73]; p = 0.761) alone did not affect overall survival in our cohort. Conclusions: Among older patients hospitalized for COVID-19, chronic OAC therapy was not associated with a reduced risk of in-hospital death. Moreover, our data suggest similar outcome both for patients on VKAs or in patients on DOACs. |
|||||
|---|---|---|---|---|---|---|
| Sprache | Englisch | |||||
| Erscheinungsdatum | 2021-07-03 | |||||
| Erscheinungsland | Germany | |||||
| Dokumenttyp | Journal Article | |||||
| ZDB-ID | 2104785-6 | |||||
| ISSN | 1720-8319 ; 1594-0667 | |||||
| ISSN (online) | 1720-8319 | |||||
| ISSN | 1594-0667 | |||||
| DOI | 10.1007/s40520-021-01924-w | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 3343: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.